ACONHIGH SIGNALFINANCIAL10-K

ACON experienced a dramatic cash infusion from $454K to $12.0M (+2,549%) while simultaneously increasing outstanding shares from 582K to 2.3M, indicating a significant equity financing event.

The massive increase in cash position and shares outstanding suggests ACON completed a substantial equity raise, providing critical funding for operations but significantly diluting existing shareholders. This capital injection appears essential given the company's negative operating cash flow of -$7.2M, which worsened from -$5.3M in the prior period.

Comparing 2026-03-18 vs 2025-04-09View on EDGAR →
FINANCIAL ANALYSIS

ACON's financials reflect a major equity financing event with cash surging 2,549% to $12.0M and total assets growing 544% to $13.7M, while shares outstanding quadrupled to 2.3M shares. Despite this capital infusion, operating cash flow deteriorated 36% to -$7.2M, though the company showed modest operational improvements with revenue increasing 66% to $76K and interest expense plummeting 90% to $64K. The dramatic cash increase provides a lifeline for this cash-burning operation, but the worsening burn rate and massive dilution present significant concerns for existing shareholders.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+2548.6%
$454K$12.0M

Cash position surged 2548.6% — strong cash generation or capital raise providing significant financial cushion.

Current Assets
Balance Sheet
+1403.9%
$824K$12.4M

Current assets grew 1403.9% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+1223.1%
$970K$12.8M

Equity base grew 1223.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+543.9%
$2.1M$13.7M

Asset base grew 543.9% — expansion through organic growth, acquisitions, or capital deployment.

Capital Expenditure
Cash Flow
+320.9%
$5K$22K

Capital expenditure jumped 320.9% — major investment cycle underway; assess returns on deployment.

Gross Profit
P&L
+117.5%
-$39K$7K

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Interest Expense
P&L
-89.5%
$608K$64K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Revenue
P&L
+65.6%
$46K$76K

Strong top-line growth of 65.6% — accelerating demand or successful expansion into new markets.

Accounts Receivable
Balance Sheet
+62%
$18K$30K

Receivables surged 62% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Operating Cash Flow
Cash Flow
-35.9%
-$5.3M-$7.2M

Operating cash flow fell 35.9% — earnings quality concerns; investigate working capital changes and non-cash items.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-04-09
ADDED
As of March 17, 2026, 2,282,371 shares of the registrant s common stock, $0.00001 par value per share, were outstanding.
" Covered Entity is a health care provider or other person or entity who acquires and transmits private health information of patients, as covered under HIPAA and GDPR regulations (see e.g., 45 CFR 160.103).
As of December 31, 2025, our patent portfolio includes 28 U.S.
NMR equipment was used to conduct MRS chemical analysis of painful discs that were surgically removed for DLBP fusion surgery versus normal, non-painful discs that were surgically removed from spinal deformity (i.e., scoliosis) patients for lumbar spine reconstruction.
The patents subject to the License Agreement expire between 2026 and 2037, without considering any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees.
+7 more — sign up free →
REMOVED
As of April 9, 2025, 582,371 shares of the registrant s common stock, $0.00001 par value per share, were outstanding.
" Covered Entity is a health care provider or other person or entity who acquires and transmits private health information of patients, as covered under HIPAA and GDPR regulations (see e.g.
We have entered into joint ventures with certain hospitals both provide and manage their diagnostic imaging services, allowing them to leverage our industry expertise.
NMR equipment was used to conduct MRS chemical analysis of painful discs that were surgically removed for DLBP fusion surgery versus normal, non-painful discs that were surgically removed from spinal deformity (i.e.
The patents subject to the License Agreement expire between 2025 and 2029.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →